Generic Medicine Info
Indications and Dosage
Cancer therapy-induced hyperuricaemia
Adult: 0.20 mg/kg once daily given via infusion over 30 minutes for 5-7 days, depending on uric acid levels and clinical assessment.
Child: Same as adult dose.
Add 1 mL and 5 mL diluent to a vial labelled as containing 1.5 mg and 7.5 mg respectively to provide a solution containing 1.5 mg/mL. Gently swirl to mix. Do not shake. Further dilute with NaCl 0.9 % to a total volume of 50 mL.
Hypersensitivity. G6PD deficiency, and other cellular metabolic disorders causing haemolytic anaemia.
Special Precautions
Patients with history of atopic allergies. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Severe haemolytic reactions, methaemoglobinaemia.
Gastrointestinal disorders: Diarrhoea, vomiting, nausea.
General disorders and admin site conditions: Fever.
Hepatobiliary disorders: Hyperbilirubinemia, increased serum ALT.
Infections and infestations: Sepsis.
Immune system disorders: IgG and IgE antibody development.
Nervous system disorders: Headache.
Metabolism and nutrition disorders: Peripheral oedema, hypophosphataemia, hypervolaemia.
Psychiatric disorders: Anxiety.
Respiratory, thoracic and mediastinal disorders: Pharyngolaryngeal pain.
Potentially Fatal: Serious hypersensitivity reactions (e.g. anaphylactic shock).
IV/Parenteral: C
Monitoring Parameters
Perform G6PD deficiency screening prior to initiation of therapy. Monitor plasma uric acid levels 4 hours after administration then every 6-8 hours until tumour lysis syndrome resolution; CBC. Monitor for signs and symptoms of hypersensitivity reactions.
Lab Interference
May cause enzymatic degradation of uric acid in serum/blood/plasma samples when placed at room temperature resulting to low uric acid assay reading.
Mechanism of Action: Rasburicase is a recombinant form of urate oxidase enzyme, which oxidises uric acid to allantoin (a water soluble and inactive metabolite) . It is used as prophylaxis and treatment of acute hyperuricaemia associated with chemotherapy.
Onset: Within 4 hours.
Distribution: Volume of distribution: 76-138 mL/kg.
Excretion: Elimination half-life: Approx 16-23 hours.
Stored between 2-8°C. Do not freeze. Protect from light.
MIMS Class
Supportive Care Therapy
ATC Classification
V03AF07 - rasburicase ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Anon. Rasburicase. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 03/12/2018.

Anon. Rasburicase. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/12/2018.

Buckingham R (ed). Urate Oxidase. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/12/2018.

Elitek (Sanofi-aventis U.S. LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/12/2018.

Disclaimer: This information is independently developed by MIMS based on Rasburicase from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in